Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DR26FRRE0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,484.64 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml autoinjectors. The delivery order, issued on November 20, 2025, with an ultimate completion date of December 12, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award represents a specific delivery order issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Department of Defense's medical supply chain, with the underlying PPV-G GEN V contract providing a $499.999 billion ceiling and authorization to supply diverse pharmaceutical products, biologics, and medical consumables to military healthcare facilities worldwide through December 31, 2036. The company's product portfolio encompasses both specialty pharmaceuticals such as Xolair for immunological conditions and routine medications, positioning it as a key vendor for the military medical system's recurring supply requirements. This delivery order for Xolair reflects DMS Pharmaceutical Group's established performance in fulfilling the specialized pharmaceutical needs of federal defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FRRE0?
SPE2DR26FRRE0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 20, 2025.
How much is contract SPE2DR26FRRE0 worth?
The government has obligated $10,485 on SPE2DR26FRRE0.
Is contract SPE2DR26FRRE0 an order under another contract?
Yes. SPE2DR26FRRE0 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRE0 competed?
The extent of competition for SPE2DR26FRRE0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award